ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Cuproptosis Signature Would Reveal the Acute-Remitting Pattern in Patients with Neuromyelitis Optica Spectrum Disorder.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cuproptosis Signature Would Reveal the Acute-Remitting Pattern in Patients with Neuromyelitis Optica Spectrum Disorder.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
The acute-remitting course (the time interval from remission to the next relapse) is a distinct signature of neuromyelitis optica spectrum disorder (NMOSD), which harms patients and perplexes physicians. However, clinically actionable biomarkers to anticipate NMOSD relapse timing are unavailable. Recently, it is found that Cuproptosis-related genes would have an impact on the acute-remitting course in patients with aquaporin-4 (AQP4)-immunoglobulin G antibody positive NMOSD. A machine learning-based algorithm is developed to construct a consensus Cuproptosis-related prognosis risk (CRPR) model, followed by training a proportional hazards model to divide patients with NMOSD into high/low relapse risk groups. The CRPR is related to the clinical symptoms of patients with NMOSD. Finally, a nomogram is created using CRPR to predict the possibility of relapse in new cases of NMOSD. This prediction model can assist physicians and help develop appropriate interventions to prevent disease relapse.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.